• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Preclinical study demonstrates potential of IntraVacc intranasal pertussis vaccine

Vaccine developer Intravacc has published data from a preclinical study of an intranasal whooping cough vaccine demonstrating strong immune responses in mice. The intranasal vaccine also prevented colonization of the lung, trachea, and nose by B. pertussis, the bacteria that causes whooping cough, while mice vaccinated by subcutaneous injection did experience nasal colonization.

The vaccine is based on the company’s outer membrane vesicle (OMV) technology. Intravacc CEO Jan Groen commented, “This study, showing full protection against whooping cough after intranasal immunization with our OMV based pertussis vaccine, provides us with a lot of comfort towards the development of our Covid-19 intranasal vaccine based on OMV’s”

Chief Scientific Officer Gideon Kersten said, “Intravacc’s vaccine concept has several potential advantages. Because of its composition outer membrane vesicles reduce the risk of vaccination induced selection of strains not matching with the vaccine, it induces immunity at the port of entry and it is needle free, allowing easy administration and flexible incorporation in immunization programs.”

Intravacc recently announced that it had partnered with Wageningen Bioveterinary Research (WBVR) and Utrecht University to develop an intranasal Newcastle disease virus (NDV) vector vaccine for the prevention of COVID-19. 

Read the Intravacc press release.

Share

published on June 22, 2020

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews